Idiopathic Pulmonary Fibrosis Treatment Market by Treatment Type – Pharmacological Treatment (Pirfenidone (Esbriet), Nintedanib (Ofev), Generic Pirfenidone); Non-pharmacological Treatment (Oxygen Therapy, Pulmonary Rehabilitation, Mechanical Ventilation, Lung Transplantation, Other Non-Pharmacological Treatment); Patients by Disease Severity (Mild, Moderate, Severe); Drug Pipeline Analysis (AEOL-10150, Lebrikizumab, Tipelukast, Tralokinumab, FG-3019, Simtuzumab, BMS-986020, AF-219, SAR156597, BG00011, PRM-151, PBI-4050) and Forecast 2017-2021

Idiopathic Pulmonary Fibrosis Treatment Market by Treatment Type – Pharmacological Treatment (Pirfenidone (Esbriet), Nintedanib (Ofev), Generic Pirfenidone); Non-pharmacological Treatment (Oxygen Therapy, Pulmonary Rehabilitation, Mechanical Ventilation, Lung Transplantation, Other Non-Pharmacological Treatment); Patients by Disease Severity (Mild, Moderate, Severe); Drug Pipeline Analysis (AEOL-10150, Lebrikizumab, Tipelukast, Tralokinumab, FG-3019, Simtuzumab, BMS-986020, AF-219, SAR156597, BG00011, PRM-151, PBI-4050) and Forecast 2017-2021

Idiopathic Pulmonary Fibrosis (IPF) is a respiratory disease characterized by the formation of scar tissue in the lungs called fibrosis. IPF patients exhibit a rapid increase in fibrosis leading to severe breathing difficulties, a persistent cough, and difficulty in performing daily tasks. It usually affects people between 50 and 70 years old, particularly men and smokers. IPF is estimated to affect over 130,000 Americans. Every year, 48,000 new cases are diagnosed and 40,000 patients die from the disease. Treatment strategies for idiopathic pulmonary fibrosis include the assessment and management of comorbid conditions according to current practice guidelines, including chronic obstructive pulmonary disease, obstructive sleep apnea, gastroesophageal reflux disease, and coronary artery disease. Although there are two FDA-approved therapies for IPF, Esbriet (Roche) and OFEV (Boehringer-Ingelheim), there is no cure. In March 2015, Aeolus Pharmaceuticals received notice from the Office of Orphan Products Development at the U.S. Food & Drug Administration (FDA) granting Orphan Drug Designation for AEOL 10150 for treatment of idiopathic pulmonary fibrosis. Several companies are exploring potential new therapies, including MediciNova (tipelukast), Biogen (STX-100), Gilead (simtuzumab), Afferent (AF-219), and FibroGen (FG-3019).

The global idiopathic pulmonary fibrosis treatment market segmentation is based on treatment type – pharmacological treatment (pirfenidone (Esbriet), nintedanib (Ofev), generic pirfenidone); non-pharmacological treatment (oxygen therapy, pulmonary rehabilitation, mechanical ventilation, lung transplantation, other non-pharmacological treatment); patients by disease severity (mild, moderate, severe); drug pipeline analysis (AEOL-10150, Lebrikizumab, Tipelukast, Tralokinumab, FG-3019, Simtuzumab, BMS-986020, AF-219, SAR156597, BG00011, PRM-151, PBI-4050).

The global idiopathic pulmonary fibrosis treatment market research report provides market size (Revenue US$ Million 2014 to 2021), patient numbers by disease severity and by country (U.S., Japan, U.K. Germany, France, Italy, Spain, 2014 to 2021), market share analysis, growth trends and forecast (CAGR%, 2017 to 2021). The global idiopathic pulmonary fibrosis treatment market research report is further segmented by geography into North America (U.S., Canada), Latin America (Brazil, Mexico, Rest of LA), Europe (U.K., Germany, France, Italy, Spain, Rest of EU), Asia Pacific (Japan, China, India, Rest of APAC), and Rest of the World. In addition, the global idiopathic pulmonary fibrosis treatment market report provides the detailed market landscape (market drivers, restraints, opportunities), market attractiveness analysis, and market profitability analysis by key products and regions or countries.  The report also tracks the major competitors operating in the global market by company overview, financial snapshot, major products, technologies, services offered and recent developments.

Major players operating in the global idiopathic pulmonary fibrosis treatment market and profiled in this report include Aeolus Pharmaceuticals, Baxter International, Biogen, Inc., Boehringer Ingelheim, F. Hoffmann-La Roche, FibroGen, Inc., Gilead Sciences, Inventiva Pharma, MediciNova, Inc., Merck & Co. (Afferent Pharmaceuticals, Inc.), Promedior, Inc., Prometheus Laboratories, Inc., and Shionogi & Company.

Category:
  1. Introduction
  2. Executive Summary
    • Market Size Estimation (Revenue US$ Million, 2014-2021)
    • Forecast Estimation (Revenue US$ Million and CAGR%, 2017-2021)
  3. Research Methodology
  4. Market Landscape
    • Market Dynamics
      • Drivers
      • Barriers
      • Opportunities
    • Market Share Analysis
      • Companies
      • Drugs
    • Market Trends Analysis
      • Key success factors
      • Market Growth Rate
    • Market Attractiveness Analysis
    • Market Profitability Analysis
      • Buyer power
      • Supplier power
      • Barriers to entry
      • Threat of substitute products
      • Rivalry among firms in the industry
    • Distribution Channels
  5. Market Segmentation [refer Market Segments and Companies Tab]
    • Drug Class or Drug (Brand) Type
    • Drug or Disorder Test
    • Indication Type
    • Drug Treatment
    • Mechanism of Action
    • Therapeutic Area or Nature of Application
    • End User Groups
  6. Geography (Region, Country)
    • North America (U.S., Canada)
    • Europe (U.K., Germany, France, Italy, Spain, Rest of EU)
    • Latin America (Brazil, Mexico, Rest of LA)
    • Asia Pacific (Japan, China, India, Rest of APAC)
    • Rest of the World (Middle East & Africa)
  7. Regulatory Overview 
    • IND, NDA filed, FDA, EMEA Approvals
  8. Pipeline Analysis(Phase 1, 2 and 3 Drugs)
    • Phase 3 Drugs Forecast Estimation (Approval to 2025)
    • Phase 1 and 2 Drugs – Qualitative Analysis
  9. Company Profiles [refer Market Segments and Companies Tab]
    • Company Overview
    • Financial Snapshot (FY 2014-2016)
    • Product Portfolio
    • Business Strategies
    • Recent Developments
  10. Recommendations
  11. References

Idiopathic Pulmonary Fibrosis Treatment Market

1. Treatment Type
1.1. Pharmacological Treatment – Drug (Brand)
1.1.1. Pirfenidone (Esbriet)
1.1.2. Nintedanib (Ofev)
1.1.3. Generic Pirfenidone
1.2. Non-pharmacological Treatment
1.2.1. Oxygen Therapy
1.2.2. Pulmonary Rehabilitation
1.2.3. Mechanical Ventilation
1.2.4. Lung Transplantation
1.2.5. Other Non-Pharmacological Treatment

2. Patients (Disease Severity)
2.1. Mild
2.2. Moderate
2.3. Severe

3. Pipeline Analysis
3.1. AEOL-10150
3.2. Lebrikizumab
3.3. Tipelukast
3.4. Tralokinumab
3.5. FG-3019
3.6. Simtuzumab
3.7. BMS-986020
3.8. AF-219
3.9. SAR156597
3.10. BG00011
3.11. PRM-151
3.12. PBI-4050

4. Geography
4.1. North America (U.S., Canada)
4.2. Latin America (Brazil, Mexico, Rest of LA)
4.3. Europe (U.K., Germany, France, Italy, Spain, Rest of EU)
4.4. Asia Pacific (Japan, China, India, Rest of APAC
4.5. Rest of the World

5. Company Profiles
5.1. Aeolus Pharmaceuticals
5.2. Baxter International
5.3. Biogen, Inc.
5.4. Boehringer Ingelheim
5.5. F. Hoffmann-La Roche
5.6. FibroGen, Inc.
5.7. Gilead Sciences
5.8. Inventiva Pharma
5.9. MediciNova, Inc.
5.10. Merck & Co. (Afferent Pharmaceuticals, Inc.)
5.11. Promedior, Inc.
5.12. Prometheus Laboratories, Inc.
5.13. Shionogi & Company

Request market specific full ToC and sample pages for this report

Full Name*

Email*

Phone Number* [Please add country code]

Subject*

Message*